Mitsubishi UFJ Trust & Banking Corp Cuts Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Mitsubishi UFJ Trust & Banking Corp cut its holdings in shares of Exact Sciences Co. (NASDAQ:EXASFree Report) by 2.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 219,917 shares of the medical research company’s stock after selling 6,243 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.12% of Exact Sciences worth $15,003,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Segall Bryant & Hamill LLC increased its stake in shares of Exact Sciences by 4.7% during the second quarter. Segall Bryant & Hamill LLC now owns 3,315 shares of the medical research company’s stock valued at $311,000 after buying an additional 150 shares during the period. Kestra Advisory Services LLC increased its stake in shares of Exact Sciences by 0.9% during the second quarter. Kestra Advisory Services LLC now owns 17,195 shares of the medical research company’s stock valued at $1,615,000 after buying an additional 154 shares during the period. Harbour Investments Inc. grew its stake in Exact Sciences by 0.6% in the first quarter. Harbour Investments Inc. now owns 26,279 shares of the medical research company’s stock worth $1,782,000 after purchasing an additional 162 shares during the period. Strategic Blueprint LLC grew its stake in Exact Sciences by 3.1% in the third quarter. Strategic Blueprint LLC now owns 5,449 shares of the medical research company’s stock worth $372,000 after purchasing an additional 163 shares during the period. Finally, Green Alpha Advisors LLC grew its stake in Exact Sciences by 3.5% in the third quarter. Green Alpha Advisors LLC now owns 4,893 shares of the medical research company’s stock worth $334,000 after purchasing an additional 165 shares during the period. 89.13% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Sarah Condella sold 2,000 shares of the company’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00. Following the transaction, the executive vice president now directly owns 71,423 shares of the company’s stock, valued at $4,999,610. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of the stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $70.00, for a total value of $140,000.00. Following the transaction, the executive vice president now owns 71,423 shares of the company’s stock, valued at $4,999,610. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Brian Baranick sold 879 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $73.50, for a total value of $64,606.50. Following the completion of the transaction, the insider now directly owns 7,992 shares in the company, valued at approximately $587,412. The disclosure for this sale can be found here. Insiders have sold a total of 4,879 shares of company stock valued at $351,607 over the last ninety days. 1.30% of the stock is currently owned by corporate insiders.

Exact Sciences Stock Up 2.4 %

Shares of NASDAQ:EXAS opened at $62.09 on Tuesday. The company has a quick ratio of 2.13, a current ratio of 2.41 and a debt-to-equity ratio of 0.74. Exact Sciences Co. has a 1 year low of $58.43 and a 1 year high of $100.77. The stock’s fifty day moving average price is $67.42 and its 200-day moving average price is $70.69.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on EXAS shares. Guggenheim started coverage on Exact Sciences in a research note on Thursday, December 14th. They issued a “buy” rating and a $90.00 price target on the stock. The Goldman Sachs Group reduced their price target on Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. Benchmark raised Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price target on the stock in a research note on Tuesday, January 2nd. Wolfe Research started coverage on Exact Sciences in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $95.00 price target on the stock. Finally, Piper Sandler reduced their price target on Exact Sciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, October 16th. Three equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $97.06.

Get Our Latest Research Report on EXAS

About Exact Sciences

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

See Also

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.